Learner Notification

Society of Gynecologic Oncology
2024 Palliative Care Series Part II
April 2, 2024 – April 2, 2025
Online

Acknowledgement of Financial Commercial Support
AstraZeneca

Acknowledgement of In-Kind Commercial Support
No in-kind commercial support was received for this educational activity.

Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Society of Gynecologic Oncology (SGO). Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Amedco Joint Accreditation #4008163.

Physicians (ACCME) Credit Designation
Amedco LLC designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses (ANCC) Credit Designation
Amedco LLC designates this activity for a maximum of 1.25 ANCC contact hours.

Objectives - After Attending This Program You Should Be Able To
1. Distinguish between hospice and palliative care, and advance care planning and advance directives.
2. Manage and treat cancer related side effects, including fatigue, distress, depression, and anxiety.
3. Define Medical Aid in Dying (MAID) and list MAID eligibility criteria.

Disclosure of Conflict of Interest
The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco. All of these relationships were treated as a conflict of interest, and have been resolved. (C7 SCS 6.1---6.2, 6.5)

All individuals in a position to control the content of CE are listed below.

<table>
<thead>
<tr>
<th>First</th>
<th>Last</th>
<th>Commercial Interest</th>
</tr>
</thead>
<tbody>
<tr>
<td>Maria</td>
<td>Bell</td>
<td>NA</td>
</tr>
<tr>
<td>Lindsay</td>
<td>Brubaker</td>
<td>NA</td>
</tr>
<tr>
<td>Ellen</td>
<td>Hartenbach</td>
<td>NA</td>
</tr>
<tr>
<td>Katherine</td>
<td>Hicks-Courant</td>
<td>NA</td>
</tr>
<tr>
<td>Carolyn</td>
<td>Lefkowis</td>
<td>Vertex Pharmaceuticals: Other</td>
</tr>
<tr>
<td>Tracy</td>
<td>Sandstrom</td>
<td>NA</td>
</tr>
</tbody>
</table>